Obesity leads to severe long-term complications and reduced life expectancy. Roux-en-Y gastric bypass (RYGB) surgery induces excessive and continuous weight loss in (morbid) obesity, although it causes several abnormal anatomical and physiological conditions.
To distinctively unveil effects of RYGB surgery on β-cell function and glucose turnover in skeletal muscle, liver, and gut, nondiabetic, morbidly obese patients were studied before (pre-OP, five female/one male, BMI: 49 ± 3 kg/m 2, 43 ± 2 years of age) and 7 ± 1 months after (post-OP, BMI: 37 ± 3 kg/m 2) RYGB surgery, compared with matching obese (CON ob, five female/one male, BMI: 34 ± 1 kg/m 2, 48 ± 3 years of age) and lean controls (CON lean, five female/one male, BMI: 22 ± 0 kg/m 2, 42 ± 2 years of age). Oral glucose tolerance tests (OGTTs), hyperinsulinemic-isoglycemic clamp tests, and mechanistic mathematical modeling allowed determination of whole-body insulin sensitivity ( M/I), OGTT and clamp test β-cell function, and gastrointestinal glucose absorption.
Post-OP lost ( P < 0.0001) 35 ± 3 kg body weight. M/I increased after RYGB, becoming comparable to CON ob, but remaining markedly lower than CON lean ( P < 0.05). M/I tightly correlated (τ = −0.611, P < 0.0001) with fat mass. During OGTT, post-OP showed ≥15% reduced plasma glucose from 120 to 180 min (≤4.5 mmol/L), and 29-fold elevated active glucagon-like peptide-1 (GLP-1) dynamic areas under the curve, which tightly correlated ( r = 0.837, P < 0.001) with 84% increased β-cell secretion. Insulinogenic index (0–30 min) in post-OP was ≥29% greater ( P < 0.04). At fasting, post-OP showed approximately halved insulin secretion ( P < 0.05 vs. pre-OP). Insulin-stimulated insulin secretion in post-OP was 52% higher than before surgery, but 1–2 pmol/min 2 lower than in CON ob/CON lean ( P < 0.05). Gastrointestinal glucose absorption was comparable in pre-OP and post-OP, but 9–26% lower from 40 to 90 min in post-OP than in CON ob/CON lean ( P < 0.04).